Skip to main content

PEAR Therapeutics announced today that it has entered into a collaboration with Novartis to develop novel prescription digital therapeutics for schizophrenia and multiple sclerosis (MS). These digital therapeutics are software applications designed to effectively improve clinical outcomes for patients. The collaboration brings together Novartis’ expertise in neurological disorders, clinical development, and commercialization with PEAR’s leading experience in prescription digital therapeutic design and implementation.